ANAVEX LIFE SCIENCES CORP. AVXL Balance Sheet

Anavex life sciences corp. (AVXL)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Sep'10
ASSETS
Current
Cash and cash equivalents
26,563	27,458	22,185	-	-	-	22,930	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Incentive and tax receivables
4,151	3,730	2,642	-	-	-	1,870	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and deposits
-	-	-	-	-	-	1,251	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deposits - short term
-	-	-	15	15	43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Assets
-	-	-	21,817	20,549	22,095	26,052	26,742	25,812	28,291	27,785	24,854	23,554	21,321	9,446	9,843	12,114	14,022	15,468	7,977	6,362	7,048	7,351	8,198	9,222	148	393	3	0	79	12	21	189	82	200	1,276	325
Cash and cash equivalents
-	-	-	21,249	19,457	20,715	-	25,827	25,656	28,048	27,440	24,793	23,351	21,161	9,186	9,727	11,950	13,853	15,290	7,961	6,310	6,980	7,262	8,179	9,193	95	345	1	0	79	11	18	178	9	134	1,222	264
Sales tax recoverable
-	-	-	93	76	30	-	6	5	7	9	8	60	49	79	47	78	92	76	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing charge
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35	-	-	0
Prepaid expenses and deposits
305	234	500	459	849	1,155	-	858	150	235	335	52	141	110	180	68	84	77	100	16	51	67	89	18	28	52	48	-	-	-	0	0	0	34	9	32	23
VAT recoverable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3	0	21	37
Deferred costs
-	-	-	-	151	151	101	50	30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,113	1,068	-	0	1	0	0	1	2	9	-	55	-	-
Deferred costs
-	-	-	151	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deposits
-	-	-	-	-	-	52	52	52	52	52	52	52	52	52	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1	1	1	1	1	2	1	1	2	0	0	0	0	0	1	1	1	2	2	4
Total Assets
31,020	31,424	25,329	21,968	20,549	22,095	26,206	26,794	25,895	28,343	27,838	24,906	23,606	21,373	9,498	9,843	12,115	14,023	15,469	7,978	6,364	7,050	7,353	9,313	10,292	150	393	3	0	79	13	22	191	84	203	1,279	329
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable
3,649	3,127	3,523	-	-	-	2,955	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued liabilities
2,579	2,336	1,516	-	-	-	929	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
-	-	-	4,336	6,370	4,875	-	3,209	3,416	2,798	3,584	1,435	2,033	2,163	3,119	2,057	2,338	2,417	2,503	1,259	1,437	1,319	1,249	1,703	1,689	1,620	1,741	2,799	2,673	2,809	2,589	2,170	1,918	1,397	410	1,367	797
Deferred grant income
-	-	-	-	-	-	-	-	-	-	-	19	86	31	70	27	5	32	71	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	12	67	57	0
Promissory notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87	88	82	85	92	90	98	192	200	193	200	210	757	761	599	299	49	1,200	1,156	867	827	2,492
Total Liabilities
6,228	5,463	5,039	4,336	6,370	4,875	3,884	3,209	3,416	2,798	3,584	1,454	2,119	2,194	-	2,172	2,431	2,532	2,660	1,351	1,528	1,418	1,441	1,904	1,883	1,821	1,952	-	-	-	2,888	-	-	-	-	-	-
Senior Convertible Debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	5,719	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-interest bearing liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57	133	5,159	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative financial instruments - warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	904	-	-	-	0	-	-	-	-	-	-
Convertible debentures, net of debt discounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	0	-	-	-	-	-	-	-	-	-	-
Total Liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,190	2,172	2,432	2,532	2,660	1,409	1,662	6,577	7,160	1,905	1,884	1,821	2,856	3,556	3,435	3,408	2,888	2,219	3,119	2,565	1,345	2,252	3,290
Commitments and Contingencies - Note 5
-	-	-	-	-	-	-	-	0	0	-	0	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 58,664,946 common shares (September 30, 2019 - 52,650,251)
58	57	52	51	48	46	45	45	44	44	43	42	41	40	36	35	35	34	32	86	64	54	11	38	38	37	37	30	30	30	30	30	-	-	26	25	23
Additional paid-in capital
171,958	165,891	153,633	148,927	138,696	133,438	129,377	126,679	122,724	121,038	115,689	109,733	104,159	100,303	84,290	79,142	78,914	76,127	74,060	-	-	-	50,714	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65,030	59,082	53,138	-	49,604	49,595	39,078	38,644	34,599	34,599	34,599	34,599	34,524	29,329	28,869	28,034	26,782	18,912
Subscriptions receivable
-	-	-	-	-292	-	-	-	-	-	-	-	-	-	-	-	-	-	-	777	640	640	-	640	640	60	60	33	-	-	0	75	27	27	-	-	-
Common stock to be issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-2,565	-1,997	-	-	-	-640	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accumulated deficit
-147,225	-139,988	-133,396	-131,347	-124,273	-116,265	-107,101	-103,138	-100,289	-95,537	-91,478	-86,323	-82,713	-81,164	-78,018	-71,507	-69,266	-67,235	-63,281	-	-	-	-51,173	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accumulated deficit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59,325	55,084	53,360	-	42,874	41,865	40,846	41,204	38,216	38,064	37,958	37,504	36,827	32,284	31,377	29,203	27,781	21,896
Total Stockholders' Equity
24,791	25,960	20,289	17,631	14,179	17,219	22,321	23,585	22,478	25,545	24,253	23,452	21,486	19,179	6,308	7,671	9,683	11,491	12,809	6,569	4,702	473	192	7,408	8,408	-1,670	-2,463	-3,553	-3,434	-3,328	-2,875	-2,197	-2,928	-2,481	-1,142	-973	-2,960
Total Liabilities and Stockholders' Equity
31,020	31,424	25,329	21,968	20,549	22,095	26,206	26,794	25,895	28,343	27,838	24,906	23,606	21,373	9,498	9,843	12,115	14,023	15,469	7,978	6,364	7,050	7,353	9,313	10,292	150	393	3	0	79	13	22	191	84	203	1,279	329